Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 151

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 151
---
 defined in the Purchase Agreement) on the applicable Additional VWAP Purchase Date.

If we make certain issuances of our securities within a specified period of time after a Purchase Date and such securities are issued at prices, or the New Issuance Price, less than the prices to be paid bythe Selling Shareholder in such Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, the purchase price for such applicable Fixed Purchase, VWAP Purchase and Additional VWAP Purchase would be reduced to the New Issuance Price, subject to the terms and conditions set forth in the Purchase Agreement.

Under the Purchase Agreement, in no event may the aggregate amount of Purchase Shares submitted in any single or combination of VWAP Purchase notices and/or Additional VWAP Purchase notices on a particular date require a payment fromthe Selling Shareholder to us that exceeds $2,500,000, unless such limitation is waived bythe Selling Shareholder.

The Selling Shareholder is not obligated to buy any Depositary Shares pursuant to the Purchase Agreement if such Depositary Shares, when aggregated with all other securities then beneficially owned bythe Selling Shareholder and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder), would result inthe Selling Shareholder beneficially owning Ordinary Shares (represented by Depositary Shares) in excess of the Beneficial Ownership Limitation.

The net proceeds under the Purchase Agreement to us will depend on the frequency and prices at which we sell Depositary Shares tothe
Selling Shareholder. We expect that any proceeds received by us from such sales tothe Selling
Shareholder will be usedto fund our development programs, for working capital and other
general corporate purposes.

We have the right to terminate the Purchase Agreement at any time, upon one business days’ notice, at no cost or penalty. During any “suspension event” under the Purchase Agreement,the Selling Shareholder does not have the right to terminate the Purchase Agreement; however, we may not initiate any regular or other purchase of shares bythe
Selling Shareholder, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against us, the Purchase Agreement will automatically terminate in accordance with its terms.

| 77 |

There are substantial risks to our shareholders as a result of the sale and issuance of Depositary Shares tothe Selling Shareholder
under the Purchase Agreement. These risks include substantial dilution, significant declines in our stock